31909-58-7

Basic information

• Product Name: 2-FUROYLACETONITRILE
• Synonyms: BUTTPARK 82\12-56;3-(FURAN-2-YL)-3-OXOPROPANENITRILE;3-(2-FURYL)-3-OXOPROPANENITRILE;2-FUROYLACETONITRILE;SALOR-INT L132853-1EA;3-Fur-2-yl-3-oxopropanenitrile;2-Furoylacetonitrile,97%;2-Furoylacetonitrile,99%
• CAS NO: 31909-58-7
• Molecular Formula: C₇H₅NO₂
• Molecular Weight: 135.12
• Product Categories: Building Blocks;Furans;Heterocyclic Building Blocks
• Mol File: 31909-58-7.mol
• Article Data: 30

Chemical Properties

• Melting Point: 81-85 °C(lit.)
• Boiling Point: 248.79°C (rough estimate)
• Flash Point: 133.6 °C
• Appearance: Beige to light brown/Powder
• Density: 1.3124 (rough estimate)
• Vapor Pressure: 0.00137mmHg at 25°C
• Refractive Index: 1.5800 (estimate)
• PKA: 7.12±0.10(Predicted)
• BRN: 111902
• CAS DataBase Reference: 2-FUROYLACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-FUROYLACETONITRILE(31909-58-7)
• EPA Substance Registry System: 2-FUROYLACETONITRILE(31909-58-7)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36
• RIDADR: 3276
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 31909-58-7(Hazardous Substances Data)

Usage

Chemical Properties

beige to light brown powder

Uses

Different sources of media describe the Uses of 31909-58-7 differently. You can refer to the following data:
1. 2-Furoylacetonitrile is used in the synthesis of compounds that display anti-Trypanosoma cruzi activity. This is primarily for combating Chagas disease.
2. β-oxo-2-Furanpropanenitrile is used in the synthesis of compounds that display anti-Trypanosoma cruzi activity. This is primarily for combating Chagas disease.

InChI:InChI=1/C7H5NO2/c8-4-3-6(9)7-2-1-5-10-7/h1-2,5H,3H2

Upstream product

• 144223-33-6 2-furoyl-1H-1,2,3-benzotriazole 
• 75-05-8 acetonitrile 
• 62889-08-1 1-(2-furyl)-1-(trimethylsilyloxy)ethylene 
• 7677-24-9 trimethylsilyl cyanide 
• 1192-62-7 1-(2-furyl)-1-ethanone 
• 773837-37-9 sodium cyanide 
• 15109-94-1 1-(2-furyl)-2-bromoethanone 
• 88-14-2 2-furanoic acid 
• 110-00-9 furan 
• 372-09-8 cyanoacetic acid 
• 13138-21-1 diazoacetonitrile 
• 60456-77-1 4-furylbenzaldehyde 
• 595565-46-1 3-oxo-3-(2-furyl)dithiopropionic acid methyl ester 
• 326-90-9 4,4,4-trifluoro-1-(2-furanyl)-1,3-butanedione 

Downstream Products

• 140613-99-6 2,2‐dichloro‐1‐(furan‐2‐yl)ethan‐1‐one 
• 52200-21-2 3-(dimethylamino)-2-furanoyl-2-propenenitrile 
• 58589-60-9 3-furan-2-yl-4,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
• 1569-98-8 2-(furan-2-yl)-1,3-benzothiazole 

Relevant articles and documents

One-pot three-component synthesis of novel pyrazolo[3,4-b]pyridines as potent antileukemic agents

In the current study, we report on the development of novel series of pyrazolo[3,4-b]pyridine derivatives (8a-u, 11a-n, and 14a,b) as potential anticancer agents. The prepared pyrazolo[3,4-b]pyridines have been screened for their antitumor activity in vitro at NCI-DTP. Thereafter, compound 8a was qualified by NCI for full panel five-dose assay to assess its GI50, TGI and LC50 values. Compound 8a showed broad-spectrum anti-proliferative activities over the whole NCI panel, with outstanding growth inhibition full panel GI50 (MG-MID) value equals 2.16 μM and subpanel GI50 (MG-MID) range: 1.92–2.86 μM. Furthermore, pyrazolo[3,4-b]pyridines 8a, 8e-h, 8o, 8u, 11a, 11e, 11h, 11l and 14a-b were assayed for their antiproliferative effect against a panel of leukemia cell lines (K562, MV4-11, CEM, RS4;11, ML-2 and KOPN-8) where they possessed moderate to excellent anti-leukemic activity. Moreover, pyrazolo[3,4-b]pyridines 8o, 8u, 14a and 14b were further explored for their effect on cell cycle on RS4;11 cells, in which they dose-dependently increased populations of cells in G2/M phases. Finally we analyzed the changes of selected proteins (HOXA9, MEIS1, PARP, BcL-2 and McL-1) related to cell death and viability in RS4;11 cells via Western blotting. Collectively, the obtained results suggested pyrazolo[3,4-b]pyridines 8o, 8u, 14a and 14b as promising lead molecules for further optimization to develop more potent and efficient anticancer candidates.

Synthesis of α-Ketoamides from β-Ketonitriles and Primary Amines: A Catalyst-Free Oxidative Decyanation–Amidation Reaction

AN oxidative decyanation–amidation of β-ketonitriles and primary amines readily occurs using hydrogen peroxide sodium carbonate adduct (Na2CO3·1.5H2O2), K2CO3, and 1,4-dioxane. This reactio

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.